Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech companies.
Shares of Jounce more than doubled to $1.68, while Gilead's shares fell marginally in after market trading. Gilead will now be solely responsible for all further development and commercialization of GS-1811 globally. The amended deal is expected to reduce its 2022 earnings per share by 4 cents on both GAAP and non-GAAP basis.
GS-1811 is currently being evaluated in an early-stage trial for patients with solid tumors and works by selectively depleting T-cells that suppress the body's immune response and allow tumors to grow., the drugmakers had agreed to collaborate on development of GS-1811, when Gilead made an upfront payment of $85 million to Jounce. Under the initial terms, Jounce was eligible to get up to $685 million in milestone payments from Gilead, of which it has received $40 million so far.
With the amendment, Jounce will no longer receive the remaining milestone payments or any of the sales-based royalties for the therapy.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drugJounce Therapeutics Inc. shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. would completely...
Baca lebih lajut »
Lizzo Is the Leader We Need Right Now'Today, as we try to navigate a polarized country, Lizzo stands out for her ability to lead across divides without compromising who she is or what she believes.'
Baca lebih lajut »
U.S. Jewish leaders warn Israeli officials over incoming right-wing governmentThe Jewish leaders said extremist moves by the new Israeli government could seriously hamper support for Israel in the U.S.
Baca lebih lajut »
Sisters killed in central Pa. crash right before ChristmasThe Friday night crash on the Turnpike involved multiple vehicles, including a tractor-trailer.
Baca lebih lajut »
2022 Was a Year of Right-Wing Attacks—What's Next for US Democracy?It's a rocky road to a functional democratic future for the US, but fighting injustice is a long-term task.
Baca lebih lajut »
Usher mourns death of grandmother Tina: ‘I feel a bit lost right now’The “U Got It Bad” singer said he is “trying to be strong” for his family after his 87-year-old grandmother passed away in her home on Saturday.
Baca lebih lajut »